Anti-Saccharomyces cerevisiae antibodies (ASCA) and autoimmune liver diseases
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
SUMMARY: Antibodies to the baker's yeast Saccharomyces cerevisiae (ASCA), recently proposed as a serological marker of Crohn's disease, have also been detected in other autoimmune disorders. The aim of this study was to determine prevalence and clinical significance of ASCA in autoimmune liver disease. The presence of IgG and IgA ASCA was evaluated using a commercially available immunoassay in 215 patients with autoimmune liver disease (primary biliary cirrhosis, PBC, 123 cases; autoimmune hepatitis, AIH, 67 cases; primary sclerosing cholangitis, PSC, 25 cases), 48 with inflammatory bowel disease and 19 healthy blood donors. Anti neutrophil cytoplasmic antibodies with the perinuclear pattern (p-ANCA) were assessed by indirect immunofluorescence in PSC patients. The main clinical and biochemical parameters between ASCA-positive and negative patients were analysed and compared. ASCA are predominant in Crohn's disease (70%); among liver patients, PSC and AMA-negative PBC show the highest ASCA prevalence (53% and 44%). In PBC ASCA correlate with higher levels of circulating IgA (P < 0·05). In PSC the detection of either ASCA or p-ANCA is neither associated with any clinical or biochemical feature, nor with an underlying inflammatory bowel disease. ASCA can not be considered an additional serological marker of autoimmune liver disease, but the possibility of detecting such a reactivity in autoimmune liver disorders should be considered; their correlation with elevated IgA in PBC suggests that ASCA may be an indirect sign of enhanced mucosal immunity; in PSC patients neither ASCA nor p-ANCA predict the occurrence of a concomitant inflammatory bowel disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alvarez, F., Berg, P. A., Bianchi, F. B., Bianchi, L., Burroughs, A. K., Cancado, E. L., Chapman, R. W., Cooksley, W. G. E., Czaja, A. J., Desmet, V. J., et al. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80297-9 · Cited by 2,903
Self-citation
Cited by
Patients With Primary Biliary Cirrhosis React Against A Ubiquitous Xenobiotic–Metabolizing Bacterium
Selmi, C., Balkwill, D. L., Invernizzi, P., Ansari, A. A., Coppel, R. L., Podda, M., Leung, P. S., Kenny, T. P., Van De Water, J., Nantz, M. H., et al. (2003) · Hepatology · doi:10.1053/jhep.2003.50446 · Cited by 312
Gut Mycobiota in Immunity and Inflammatory Disease
Li, X. V., Leonardi, I., & Iliev, I. D. (2019) · Immunity · doi:10.1016/j.immuni.2019.05.023 · Cited by 246
Autoantibodies in primary sclerosing cholangitis
Hov, J. R., Boberg, K. M., & Karlsen, T. H. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.3781 · Cited by 187
Interpreting serological tests in diagnosing autoimmune liver diseases
Invernizzi, P., Lleo, A., & Podda, M. (2007) · Seminars in Liver Disease · doi:10.1055/s-2007-979469 · Cited by 107
Metadata
- Authors
- MURATORI, P., MURATORI, L., GUIDI, M., MACCARIELLO, S., PAPPAS, G., FERRARI, R., GIONCHETTI, P., CAMPIERI, M., & BIANCHI, F. B.
- Venue
- Clinical and Experimental Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-05-29
- Volume
- 132
- Issue
- 3
- Pages
- 473-476
- ISSN
- 0009-9104 (ISSN-L)
- 1365-2249
- OpenAlex
- W2100684647
- Cited by
- 102
- References
- 1
- FWCI
- 2.45
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anti-Saccharomyces cerevisiae antibodies (ASCA) and autoimmune liver diseases. https://app.cochat.ai/papers/10.1046/j.1365-2249.2003.02166.x
- The paper
- MURATORI, P., MURATORI, L., GUIDI, M., MACCARIELLO, S., PAPPAS, G., FERRARI, R., GIONCHETTI, P., CAMPIERI, M., & BIANCHI, F. B. (2003). Anti-Saccharomyces cerevisiae antibodies (ASCA) and autoimmune liver diseases. Clinical and Experimental Immunology. https://doi.org/10.1046/j.1365-2249.2003.02166.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.